Biosplice Therapeutics Patents

Patent portfolio assigned to Biosplice Therapeutics (verified via public assignee records). Clinical-stage biotech (osteoarthritis/Wnt pathway). Competitors are other osteoarthritis disease-modifying drug developers named in the same coverage (Galapagos/Servier, Pfizer tanezumab, Bone Therapeutics). No customers (drug developer, not a vendor). Patents confirmed: Biosplice Therapeutics Inc is current assignee on multiple Google Patents results (e.g. US10544139B2 'Treatment of osteoarthritis', reassigned from Samumed), so has_patents=true.